CILOXAN SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

から入手可能:

NOVARTIS PHARMACEUTICALS CANADA INC

ATCコード:

S03AA07

INN（国際名）:

CIPROFLOXACIN

投薬量:

0.3%

医薬品形態:

SOLUTION

構図:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3%

投与経路:

OPHTHALMIC

パッケージ内のユニット:

5ML/10ML

処方タイプ:

Prescription

治療領域:

ANTIBACTERIALS

製品概要:

Active ingredient group (AIG) number: 0123207004; AHFS:

認証ステータス:

APPROVED

承認日:

2017-04-03

製品の特徴

_CILOXAN_
_®_
_ Product Monograph _
_ _
1
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
CILOXAN
®
Ciprofloxacin Ophthalmic Solution, USP
0.3% w/v (as ciprofloxacin hydrochloride)
Antibacterial Agent
and
Pr
CILOXAN
®
Ciprofloxacin Ophthalmic Ointment, USP
0.3% w/w (as ciprofloxacin hydrochloride)
Antibacterial Agent
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, Quebec
H9S 1A9
Date of Revision:
www.novartis.ca
May 22, 2018
Submission Control No.: 210590
CILOXAN and DROP-TAINER are registered trademarks.
_CILOXAN_
_®_
_ Product Monograph _
_ _
2
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
................................................................................11
DETAILED PHARMACOLOGY
.....................................................................................11
MICROBIOLOGY............